-
Posted by
Two Blokes Apr 21 -
Filed in
Stock
-
8 views
Viemed Healthcare's stock has declined recently, but bullish EPS revisions and strong growth projections make it an attractive buy near its long-term bottom. The company projects significant revenue and EBITDA growth for 2025, with EPS expected to rise by 42.86% in 2025 and 52.5% in 2026. Viemed's valuation remains attractive, with positive cash flow and rising equity, despite the stock's recent bearish trend.
